WHAT EVERY CARDIOLOGIST SHOULD KNOW ABOUT H1N1?

Allahyar Golabchi(1), Nizal Sarrafzadegan(2)

Abstract

The world is witnessing ever fastest growing pandemic with high morbidity and mortality that excessive volume of airline travels spread influenza infection; so physicians with various specialties should know and consider the impact of current pandemic on their daily practice. Among influenza A viruses that infect humans, an influenza A virus emerged that had shifted to H1N1. Primarily, the results of pandemic of H1N1 were in younger humans without preexisting immunity. Attack rates of swine influenza are relatively high, but mortality is relatively low and mortality rate is highest in the very young, the very old, and the immunosuppressed. In this new pandemic, there is not more evidence of the interface of H1N1 with chronic diseases; however, we expect that the Swine flu such as the previous influenza pandemics can change the course of many chronic diseases.

In this review, we want to show the impacts of swine flu on cardiovascular system and disease. We will also discuss the importance of vaccination in chronic cardiovascular disease.

Keywords: H1N1 virus, Vaccination, Cardiovascular disease, Myocarditis.

ARYA Atherosclerosis Journal 2010, 6(3)

Introduction

The world is witnessing ever fastest growing pandemic with high morbidity and mortality that excessive volume of airline travels spread influenza infection; so physicians with various specialties should know and consider the impact of current pandemic on their daily practice. Among influenza A viruses that infect humans, three major subtypes of hemagglutinins (H1, H2, and H3) and two subtypes of neuraminidases (N1 and N2) have been described. In 1977, an influenza A virus emerged that had shifted to H1N1. Primarily, the results of pandemic of H1N1 were in younger humans without preexisting immunity. Attack rates of swine influenza are relatively high, but mortality is relatively low and mortality rate is highest in the very young, the very old, and the immunosuppressed. Influenza A prevalence begins abruptly, peak over a two to three week period, and last for two to three months, classically. Most outbreaks have incidence rates of 10 to 20 percent in the general population, but rates can exceed 50 percent in pandemics. Tshibane et al. showed that people born in or before 1915 had neutralizing antibody responses to the swine influenza strain derived from the B cells that caused presumably, the 1918 pandemic, even ninety years after its outbreaks. By genetically methods, they also cross-reacted with similar hemagglutinins of a 1930 H1N1 influenza. In 1918 and 1919 pandemic of swine flu resulted in approximately 20 to 50 million deaths worldwide and was exceptionally high death among healthy adults aged 15 to 34 years; also, in 2009 pandemic, near one-third of severe cases had no underlying conditions with lower median age than the previous seasonal flu. In this new pandemic, there is not more evidence of the interface of H1N1 with chronic diseases; however, we expect that the swine flu such as the previous influenza pandemics can change the course of many chronic diseases.

In this review, we want to show the impact of swine flu on cardiovascular system and disease. We will also discuss the importance of vaccination in chronic cardiovascular disease.

Myocarditis by flu virus

The majority of our knowledge about influenza myocarditis came from isolated case reports and series. The incidence rate of the influenza A myocarditis was 9% in the study of Karjalainen et al. Perimyocarditis typically occur between 4 and 9 days after the onset of influenza symptoms with worsening dyspnea. Electrocardiogram may show new changes, such as: ST elevation, Q waves and Left Bundle Branch Block. Cardiac enzyme (CK-MB and Troponin I) levels elevate in all the patients and reduced left ventricular function exists in most patients. Even fulminant myocarditis can occur with a
distinct onset always within the first 2 weeks. Some patients present with profound left ventricular dysfunction. The endomyocardial biopsy shows multiple foci of active inflammation and necrosis. Patients recover or die within 2 weeks with complete histological and functional recovery of the myocardium. Influenza myocarditis can result in the development of a dilated cardiomyopathy as a late sequel. Pericardial effusion can exist with significant volume to cause cardiac tamponade. In H1N1-infected children has reported high incidence of myocarditis, so early detection and aggressive management are paramount. Increasing the awareness of influenza myocarditis may help in the earlier detection and treatment of this disease during influenza epidemics.

**Acute coronary syndrome and flu virus**
The influenza A infection showed a rise in Acute Myocardial Infarction (AMI), Chronic Ischemic Heart Disease (IHD) and subsequently mortality during epidemics. This effect was observed in both genders at all age groups. A study in the United States have previously estimated that influenza causes up to 92000 deaths per year by triggering AMI. Generally, cardiologists whose patients have had influenza followed by fatal myocardial infarction reported myocardial infarction mortality related to traditional risk factors not influenza infection, which is a neglected risk factor. The first 3–5 days within influenza infection is the highest risk time for AMI. Also, in patients with influenza and pneumonia, AMI may be missed as findings of dyspnea, chest pain, fever and leucocytosis are considered related to pneumonia alone.

**Mechanism of atherogenesis by flu virus**
The positive correlation between antibodies to influenza A virus and antibodies to oxidized low density lipoproteins titers show that activated autoimmune system may lead to the susceptibility to atherosclerosis. Other proposed potential mechanisms include: (1) an increase in pro-inflammatory, prothrombotic cytokines; (2) endothelial dysfunction; (3) increased plasma viscosity; (4) psychological stress; (5) decreased supply of the heart such as dehydration leading to hypotension; (6) increased demand of the heart such as tachycardia; (7) loss of the anti-inflammatory properties of HDL particles; (8) increase in invasion of macrophages into the arterial wall; (9) reduction in clotting time due to pronounced expression of inflammatory cytokines by infected monocytes; (10) atherosclerotic changes in the walls of arteries in patients with influenza and apolipoprotein-E deficiency.

**Treatment**
We can use the new neuraminidase-inhibitors such as oseltamivir (Tamiflu) and zanamivir (Relenza) in patients with silent or clinical symptoms who are exposed to influenza, but did not receive the influenza vaccine or their immune response to the vaccine is inadequate. Studies suggest that oseltamivir treatment for influenza is associated with significant decrease in mortality in patients with history of cardiovascular disease. In influenza myocarditis, treated patients with intravenous ribavirin has demonstrated that influenza viral titres declined abruptly following the initiation of therapy, although case reports have showed that supportive treatment with plasmapheresis has been successful. In trials on mice, immunoglobulin therapy suppressed influenza A virus myocarditis by increasing neutralizing titers. We can use inotropic agents and other left ventricular support devices in patients presenting with cardiogenic shock.

**Flu vaccine in organic heart disease**
In influenza pandemics, cardiovascular death surpassed other causes of mortality. Studies show an association between influenza vaccination with reduced risk of non-fatal MI, recurrent ischemic events in patients suffering from infarction or post-angioplasty during flu season. also, all-cause mortality rate was reduced by 50%. The American Heart Association (AHA) and the American College of Cardiology (ACC) recommended influenza vaccination in children and adults with coronary and other atherosclerotic vascular diseases as part of secondary prevention, also no harmful effects were seen in individuals with chronic cardiovascular diseases who received influenza vaccination. Vaccination in patients on long-term anticoagulant therapy was reported to be safe too. Inactivated influenza vaccines can be administered safely to heart transplant recipients without an increased incidence of rejection or infection. Vaccination is also administrated for
Conclusion

In summary, there is mounting evidence that influenza especially in epidemics and pandemics can trigger myocardial infarction, stroke, and sudden cardiac death. The role of influenza in cardiovascular disease is neglected in Cardiology textbooks and practice of the physicians. Furthermore, influenza vaccine is cost-effective for some groups such as chronic cardiovascular diseases. Rates of vaccination are below the optimal level in most countries. To increase influenza vaccination of patients at high risk groups an intense public health effort is needed and cardiologists need to improve vaccination rates by actively advocating vaccination following the recent AHA/ACC guidelines. Also, special attention should be paid to symptoms and signs of high risk cardiovascular patients who have an upper respiratory tract infection because direct myocardial involvement is not rare in any pandemics of influenza. We conclude that broadened indications for influenza vaccination and treatment, together with targeted prevention efforts, will save many people with cardiovascular diseases.

Conflict of Interests

Authors have no conflict of interests.

References

1. Brownstein JS, Wolfe CJ, Mandl KD. Empirical evidence for the effect of airline travel on inter-regional influenza spread in the United States. PLoS Med 2006; 3(10): e401.
2. Cunha BA. Swine Influenza (H1N1) pneumonia: clinical considerations. Infect Dis Clin North Am 2010; 24(1): 203-28.
3. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978; 298(11): 587-92.
4. Monto AS, Kroumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol 1975; 102(6): 553-63.
5. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455(7212): 532-6.
6. Kendal AP, Schieble J, Cooney MK, Chin J, Foy HM, Noble GR. Co-circulation of two influenza A (H3N2) antigenic variants detected by virus surveillance in individual communities. Am J Epidemiol 1978; 108(4): 308-11.
7. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58(27): 749-52.
8. Karjalainen J, Nieminen MS, Heikila J. Influenza A1 myocarditis in conscripts. Acta Med Scand 1980; 207(1-2): 27-30.
9. Onitsuka H, Imamura T, Miyamoto N, Shibata Y, Kashiwagi T, Ayabe T, et al. Clinical manifestations of influenza a myocarditis during the influenza epidemic of winter 1998-1999. J Cardiol 2001; 37(6): 315-23.
10. Richardson P, McKenna W, Bristow M, Maish B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93(5): 841-2.
11. Mamas MA, Nair S, Fraser D. Cardiac tamponade and heart failure as a presentation of influenza. Exp Clin Cardiol 2007; 12(4): 214-6.
12. Bratincsak A, El Said HG, Bradley JS, Shayan K, Grossfeld PD, Cannavino CR. Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children. J Am Coll Cardiol 2010; 55(9): 928-9.
13. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 2003; 108(22): 2730-6.
14. Madjid M, Casscells SW. Of birds and men: cardiologists' role in influenza pandemics. Lancet 2004; 364(9442): 1309.
15. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351(25): 2611-8.
16. Gurevich VS. Influenza, autoimmunity and atherogenesis. Autoimmun Rev 2005; 4(2): 101-5.
17. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001; 103(18): 2283-8.
18. Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ. Procoagulant and inflammatory response of virus-infected monocytes. Eur J Clin Invest 2002; 32(10): 759-66.
19. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J 2004; 31(1): 4-13.
20. Madjid M, Litovsky S, Vela D, Casscells W. Influenza vaccination: an emerging opportunity to
prevent cardiovascular disease. International Congress Series 2004; 1263: 678-81.

21. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes 2009; 2(2): 108-15.

22. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 1989; 159(5): 829-36.

23. Tabbutt S, Leonard M, Godinez RI, Sebert M, Cullen J, Spray TL, et al. Severe influenza B myocarditis and myositis. Pediatr Crit Care Med 2004; 5(4): 403-6.

24. Kishimoto C, Hiraoka Y, Takada H. Effects of immunoglobulin upon murine myocarditis caused by influenza A virus: superiority of intact type to F(ab')2 type. J Cardiovasc Pharmacol 2004; 43(1): 61-7.

25. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007; 28(10): 1205-10.

26. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105(18): 2143-7.

27. Gurfinkel EP, Leon dLF, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004; 25(1): 25-31.

28. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102(25): 3039-45.

29. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344(12): 889-96.

30. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348(14): 1322-2.

31. Ciszewski A, Bilinska ZT, Brydak LB, Kapka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29(11): 1350-8.

32. Keshtkar-Jahromi M, Vakili H, Rahnavardi M, Gholamin S, Razavi SM, Eskandari A, et al. Antibody response to influenza immunization in coronary artery disease patients: a controlled trial. Vaccine 2009; 28(1): 110-3.

33. Iorio AM, Camilloni B, Basileo M, Guercini F, Conti S, Ferrante F, et al. Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine 2006; 24(44-46): 6624-8.

34. Sibley WA, Bamford CR, Laguna JF. Influenza vaccination in patients with multiple sclerosis. JAMA 1976; 236(17): 1965-6.

35. White-Williams C, Brown R, Kirklin J, St Clair K, Keck S, O'Donnell J, et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients? J Heart Lung Transplant 2006; 25(3): 320-3.

36. Fiore AE, Shag DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7): 1-60.